BXCL101 (BioXcel Therapeutics)

  • Trial Availability: USA
  • Tumor Target: Schwannoma and Meningioma
  1. "BioXcel's BXCL101, Receives Orphan Drug Designation from the U.S. FDA for the Treatment of Patients with Neurofibromatosis Type 2 (NF2)" (Sept. 13, 2016) http://www.einnews.com/pr_news/344530804/bioxcel-s-bxcl101-receives-orphan-drug-designation-from-the-u-s-fda-for-the-treatment-of-patients-with-neurofibromatosis-type-2-nf2
What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2017